跳至主要内容
临床试验/NCT03670225
NCT03670225已完成不适用

Evaluating Clinical Acceptance of a NPWT Wound Care System to Expected Standards of Care in Post-acute Patients With a Variety of Wound Types

Medela AG1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年10月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Medela AG
入组人数
10
试验地点
1
主要终点
Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds

研究概览

简要总结

Determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.

详细描述

The primary objective of this study is to determine acceptable progress towards the goal of therapy for a diabetic foot ulcers (DFU) and pressure Injuries/ulcers (PI/PU) wounds when using the Medela Invia Motion Endure NPWT system during 4-week study duration.

Goal of therapy will be defined by the physician according to initial assessment:

Endpoints (dependent on goal of therapy):

  • Decrease in wound volume
  • Decrease in size of the tunneling area
  • Decrease in size of undermining
  • Decrease in amount of slough
  • Increase in granulation tissue
  • The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft.

**Study endpoint will be determined by physician at the time of enrollment, when the goal of therapy is documented**

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult subjects ≥18 years of age.
  • •Signed, informed consent by patient or LAR within 72 hours of admission to burn center.
  • •Patient is determined to be in need of NPWT for treatment of a diabetic foot ulcer, pressure injuries/pressure ulcer.
  • •Patient is comfortable (e.g. not in pain)
  • •Patient is willing and able to adhere to treatment protocol.

排除标准

  • •Patient not willing to comply with f/u clinic visits.
  • •Subjects with
  • •Necrotic tissue with eschar present
  • •Untreated osteomyelitis
  • •Non-enteric and unexplored fistulas
  • •Malignancy in wound
  • •Exposed vasculature
  • •Exposed nerves
  • •Exposed anastomotic site of blood vessels or bypasses
  • •Exposed organs
  • •Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
  • •Patients with concurrent conditions or co-morbidities that in the opinion of the investigator may compromise patient safety or study objectives.

研究组 & 干预措施

Invia Motion Endure

Other

干预措施: Invia Motion Endure (Device)

结局指标

主要结局

Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds

时间窗: 4 weeks

Goal of the therapy will be defined by the physician according to initial assessment: * Decrease in wound volume * Decrease in size of the tunneling area * Decrease in size of undermining * Decrease in amount of slough * Increase in granulation tissue * The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft. \*\*Study endpoint will be determined by physician at the time of enrolment, when the goal of therapy is documented\*\*

次要结局

  • Evaluation of ease of use and satisfaction(4 weeks)

研究者

发起方
Medela AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验